Metabolic activation enzymes (MAE) (MAE)

Metabolic activation enzymes are a diverse group of proteins, primarily enzymes, that catalyze the chemical transformation of xenobiotics into more polar or reactive metabolites. This process, often termed bioactivation, is a fundamental requirement for the efficacy of pro-drugs, which are pharmacologically inactive until converted by these enzymes (Guengerich, 2008, Chemical Research in Toxicology). Key enzyme families involved in these processes include the Cytochrome P450 (CYP) monooxygenases, sulfotransferases (SULTs), and UDP-glucuronosyltransferases (UGTs) (Park et al., 2005, Drug Metabolism Reviews). While essential for activating therapeutic agents like tamoxifen or clopidogrel, these enzymes can also inadvertently produce highly reactive electrophilic intermediates from otherwise inert compounds (NIH, PubChem). These reactive species can form covalent adducts with DNA or proteins, leading to mutagenicity, carcinogenicity, or idiosyncratic drug-induced liver injury (PubMed, 2021). Consequently, the study of these enzymes is critical for drug development, as genetic polymorphisms and drug-drug interactions involving these pathways are major drivers of clinical variability and safety risks (FDA, 2020).

Other names

Xenobiotic-metabolizing enzymesBioactivation enzymesPhase I and Phase II enzymesDrug-metabolizing enzymes (DME)

Enzymatic conversion of pro-drugs into active pharmacological agents or the transformation of xenobiotics into reactive, potentially toxic intermediates through oxidation, reduction, hydrolysis, or conjugation.